Open AccessBroad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
Author(s) -
Jimin Xu,
PeiYong Shi,
Hongmin Li,
Jia Zhou
Publication year - 2020
Publication title -
acs infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.324
H-Index - 39
ISSN - 2373-8227
DOI - 10.1021/acsinfecdis.0c00052
Subject(s) - niclosamide , repurposing , drug repositioning , antiviral drug , drug , virology , covid-19 , potency , medicine , pharmacology , antiviral therapy , broad spectrum , disease , biology , virus , infectious disease (medical specialty) , chemistry , ecology , biochemistry , combinatorial chemistry , in vitro , chronic hepatitis
The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom